Meropenem Venus Pharma

Meropenem, the active ingredient in Meropenem Venus Pharma, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections in hospitalized patients, including intra‑abdominal, urinary, respiratory, and central nervous system infections. GNH USA supplies Meropenem Venus Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem Venus Pharma is a carbapenem antibiotic used to treat serious infections caused by susceptible bacteria. - Complicated intra‑abdominal infection: provides broad‑spectrum bactericidal activity against Gram‑negative and Gram‑positive organisms. - Complicated urinary tract infection: eradicates resistant uropathogens including ESBL‑producing strains. - Hospital‑acquired pneumonia: targets multidrug‑resistant respiratory pathogens. - Bacterial meningitis: achieves therapeutic concentrations in cerebrospinal fluid. - Sepsis and septic shock: offers rapid bacterial clearance in critically ill patients.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis after infusion. - Rash: mild skin erythema or pruritus. - Headache: transient cranial discomfort. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction with hypotension and airway compromise. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Thrombophlebitis: inflammation at infusion site. - Renal impairment: worsening kidney function in susceptible patients. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Meropenem should be used with careful clinical monitoring. - Renal function assessment: adjust dose in patients with impaired clearance. - Neurological monitoring: observe for seizures, particularly in those with CNS disease. - Hypersensitivity screening: avoid in individuals with known carbapenem allergy. - Concomitant nephrotoxic drugs: use caution when combined with other renal‑toxic agents. - Pregnancy and lactation: prescribe only if benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to the interaction severity.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking loss of seizure control. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined use can increase nephrotoxicity. - Loop diuretics: may further reduce renal clearance of meropenem. - Warfarin: monitor INR as meropenem can alter anticoagulant effect.